✦ LIBER ✦

OL-015 A pharmacogenomics approach to predict the efficacy of HBeAg-positive chronic hepatitis B patients with pegylated interferon treatment

✍ Scribed by Y.C. Hwang; G.K.K. Lau; J.H. Kao; W.L. Chuang; C.Y. Peng; X.X. Zhang; M. Wan; K.H. Liang; E. Chao; E.Y. Chen

Book ID: 118616830
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 63 KB
Volume: 12
Category: Article
ISSN: 1201-9712
DOI: 10.1016/s1201-9712(09)60112-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of the response to peg-interf

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d

Quantification of serum hepatitis B surf

Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure

✍ Weng, Min; Zeng, Wei-Zheng; Wu, Xiao-Ling; Zhang, Yong; Jiang, Ming-De; Wang, Zh 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 150 KB

917 ON-TREATMENT MONITORING OF HBsAg LEV

917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B

✍ G.K.K. Lau; P. Marcellin; M. Brunetto; T. Piratvisuth; H.-P. Kapprell; D. Messin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Efficacy of pegylated interferon alpha-2

Efficacy of pegylated interferon alpha-2B in combination with ribavirin in patients with chronic hepatitis C non-responders to a previous treatment

✍ M. Chousterman; V. Auray-Cartier; H. Hagege; J.P. Arpurt; P. Cassan; J. Denis; D 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Interferon alpha2a in combination with l

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg(−) hepatitis B non-responders to interferon monotherapy

✍ Maria Raptopoulou-Gigi; Emanuel Sinakos; Helen Orphanou; Thalia Lalla 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 109 KB

913 EXTENDING THE TREATMENT DURATION OF

913 EXTENDING THE TREATMENT DURATION OF PEGINTERFERON ALFA-2A THERAPY TO 72 WEEKS INCREASES THE RATE OF HBeAg SEROCONVERSION IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B

✍ Y.-Y. Zhu; J. Dong; Y.-T. Chen; J. Chen; J.-J. Jiang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB